Springfield Hospital

I read with great interest the recent article by Nahid et al. [1], “Effectiveness of Shacklock's Neural Mobilization for Acute and Sub-Acute Lumbar Disc Prolapsed: A Randomized Controlled Trial.” While the topic is clinically important, several methodological and reporting issues merit clarification, as they may mislead readers regarding the effectiveness of the intervention. First, the authors describe this as a “double-blinded randomized controlled trial”, claiming that the assessor, physiotherapists, and participants were all blinded. However, this assertion is problematic and requires clarification. The intervention involved manual delivery of neural mobilization techniques, a hands-on procedure that inherently reveals group allocation to both therapist and patient. The report further notes that only two of the four treating physiotherapists were trained in neural mobilization, which would make true blinding of therapists infeasible. Likewise, participant blinding is highly questionable, given the distinct nature of the interventions received. Therefore, blinding of therapists and participants should not be claimed without a detailed and credible explanation of how it was operationalized and verified. Second, in Section 3.1 and Table 3, the authors report results from a Wilcoxon signed-rank test and interpret these as between-group differences. However, this test is designed for within-group comparisons [2]. Despite this, the authors state that “most of the variables were significant differences found on the Posttest Dallas pain score between the two groups”, which is factually incorrect. No appropriate between-group analysis is presented to support that claim. Figure 2, described as illustrating “posttest mean pain between both groups,” presents the same data as Table 3, which reflects pre- and posttreatment values likely from the experimental group alone. No data from the control group are displayed, and no between-group comparisons are provided. Therefore, both the figure caption and the accompanying interpretation are misleading and may give readers the false impression that a between-group analysis was performed and yielded significant differences. Third, the authors report using the Dallas Pain Questionnaire (DPQ) as an outcome measure; however, the items presented in Table 3 do not correspond to the validated version of the DPQ. The original DPQ consists of 16 items organized into four domains: daily activities, work/leisure activities, emotional status, and social interest [3]. In contrast, the version used in this study focuses narrowly on position-specific or task-specific pain and omits the psychosocial dimensions. No rationale is provided for modifying the tool, nor is any evidence offered regarding the reliability, validity, or cross-cultural adaptation of this version. This mislabeling not only limits the comparability of results to existing literature but also introduces the risk of measurement bias, as the unvalidated instrument may not accurately or consistently capture the intended constructs related to pain and function. Fourth, the abstract and conclusion sections emphasize that Shacklock's neural mobilization had a “significant impact” on pain and disability. However, the study's own results show that no statistically significant differences were observed between groups post-intervention on either the Dallas Pain Questionnaire or the Oswestry Disability Index. While within-group improvements were noted in the experimental group, similar improvements were also seen in the control group, and between-group comparisons did not support the added benefit of neural mobilization. Therefore, the addition of Shacklock's neural mobilization to standard physiotherapy did not result in superior outcomes, and its utility should not be interpreted as clinically effective based on this evidence. Overstating efficacy based on within-group differences alone may mislead clinicians and readers. In conclusion, while the exploration of neural mobilization in lumbar disc prolapse is timely and relevant, the interpretation of statistical findings, presentation of outcome measures, and overstatement of conclusions in this study warrant careful reconsideration. I encourage the authors to clarify these aspects to promote accurate reporting and evidence-based clinical practice. Jie Hao: conceptualization, methodology, writing – original draft, writing – review and editing. The author has nothing to report. The author declares no conflicts of interest. The author confirms that the results and interpretations presented in this letter are transparent, and the methodology used in the study is clearly documented. All analyses were conducted without manipulation or selective reporting. The author has nothing to report.

Aortic dissection is a critical and life-threatening condition that can present with atypical symptoms, often leading to misdiagnosis and delayed treatment. The report presents a case of a 65-year-old male who initially exhibited fever, right-sided chest pain, and a productive cough, resulting in an initial diagnosis of pneumonia. Despite empirical antibiotic therapy, his symptoms persisted, prompting further investigation. A computed tomography (CT) scan ultimately revealed a Type B aortic dissection. The patient was then transferred to a specialized tertiary care facility for successful endovascular intervention. This case underscores the importance of considering aortic dissection in patients presenting with persistent, atypical symptoms that do not respond to standard treatments, such as unexplained fever and chest pain. It highlights the crucial role of advanced imaging techniques, such as CT scans, in achieving an accurate and timely diagnosis. Clinicians must maintain a high index of suspicion and ensure prompt referral to specialized centers to improve patient outcomes in this potentially fatal condition.

The characteristic structural anomaly of the heart in the left ventricular non-compaction (LVNC) is identified with a prominent layer of the trabecular meshwork, thin compacted myocardium, and intertrabecular recesses within the depths of the left ventricle. Despite growing clinical recognition, the prevalence of LVNC in adults and the full clinical spectrum remain poorly explored. The disease shows heterogeneous phenotypes from an asymptomatic presentation to severe cardiac complications like cardiac failure, arrhythmias, and thromboembolic events. Current diagnostic practices for LVNC lack standardized guidelines, making patient management difficult. We here report a case of an adult patient who presented with features of congestive cardiac failure and on detailed imaging with echocardiogram and magnetic resonance imaging (MRI) was diagnosed to have LVNC. We here also emphasize that there is a great need for refined diagnostic criteria that include genetic, clinical, and imaging data. Cases of LVNC with full-blown phenotypic expression should be used for diagnostic criteria.

The online environment brings both challenges and opportunities. The skills learned in journal clubs remain highly relevant where the ability to critique rapidly generated information and apply evidence to patient care is vital. Creativity and flexibility are needed to ensure that learners' needs are met and efforts are made to involve those who may not be naturally drawn to online environments. This article explores how journal clubs have been approached in the past, both in person and more recently online, considers techniques for maintaining engagement in online teaching and proposes new approaches for future journal clubs.

Lipomas are extremely common benign tumors that occur in a variety of locations. However, lipomas in the bronchus are exceptionally rare and account for a very small number of all bronchial tumors. Diagnosis of an endobronchial lipoma can be challenging at times, as they may present with overlapping symptoms of central airway obstruction, pneumonia, or dyspnea.We present an 82-year-old male with a 40-pack-year history of smoking who presented with recurrent pneumonia and signs of airway obstruction. Imaging studies showed an obstructive lesion. The biopsy sample revealed adipose cells. Eventually, the lesion was successfully resected. The surgical specimen ruled out malignancy and confirmed the diagnosis of lipoma.Timely identification and differentiating a malignant lesion from benign lesions, like lipoma, is crucial to management.

\nBackground: Accumulating evidence suggests minocycline (MINO) is effective as an adjunct treatment in schizophrenia. We previously reported significant improvement in avolition, anxiety/depression and working memory and a trend for positive symptoms and total Brief Psychiatric Rating Scale (BPRS) scores with MINO in a double-blind, placebo-controlled trial. We also found a >30% reduction in total BPRS scores in 25% of the MINO group compared to 4% in placebo (PÂ =Â .04). Here we examine variables associated with symptom improvements.

Background: Hyperprolactinemia, a side effect of antipsychotic treatment, causes amenorrhea, oligomenorrhea, galactorrhea, gynecomastia, and sexual dysfunction. These side effects increase risk of antipsychotic nonadherence and pose significant problems in the long-term management, particularly in women with severe mental illness. Methods: Women with antipsychotic induced hyperprolactinemia and experiencing a prolactin related side effect were recruited for a 16-week double-blind randomized placebo controlled trial of adjunct aripriprazole (5 to 15 mg day). Participants with DSM-IV schizophrenia or bipolar disorder were included. Participants were seen every 2 weeks for prolactin levels, breast exams, menstrual diary review and side effect monitoring. Other assessments were performed monthly. Results: Forty-six women were randomized to treatment (N = 25 aripiprazole, N = 21 placebo). Thirty-seven completed the study (N = 20 (80%) aripiprazole and N =17 (81%) placebo). The mean age was 36.6 ± 9.4 years and 62% were African American. The mean baseline prolactin level was 84.3 ± 56.6, 23/37 (62%) had galactorrehea, 24/37 (65%) had oligomenorhea/ amenorrhea and 25/37 (68%) had sexual dysfunction at baseline. The prolactin level significantly decreased in the aripiprazole group compared to placebo (estimated difference −26.3 ± 12.6, df = 35, P = .04). Seventy-seven percent (10/13) improved or remitted on galactorrhea in the aripiprazole vs 33% (4/12) in the placebo group (Chi-Square = 4.8, df = 1, P = .028). Normal menstruation resumed in 46% and 27% in the aripiprazole and placebo groups, respectively (P = .34). With regards to sexual dysfunction, 5/20 (25%) women in the aripiprazole group had a >20% improvement in the ASEX compared to none in the placebo group (P = .03). Conclusion: Two-thirds of premenopausal women with severe mental illness treated with prolactin elevating medications experience galactorrhea, oligomenorrhea/amenorrhea and sexual dysfunction. Low dose aripiprazole is effective at lowering prolactin levels relative to placebo and it is particularly effective at improving galactorrhea in about 77% of women, menstruation in about 46% and sexual dysfunction in about a quarter of women. This and other accumulating data suggest that adjunct aripriprazole is a useful strategy for treating antipsychotic-induced symptomatic hyperprolactinemia in women.

Anaphylaxis is an unanticipated, acute, and sometimes life-threatening systemic reaction with variable clinical presentations that is typically mediated by immunoglobulin E and causes degranulation of mast cells and basophils. The onset of symptoms can occur within minutes or hours after exposure to a known or suspected trigger, and reactions sometimes progress very rapidly, which can lead to death. One trigger of anaphylaxis in younger adults is moderately intense physical exercise, which has been termed exercise-induced anaphylaxis (EIA). Although rare, EIA should be recognized as a distinct and potentially life-threatening form of physical allergy, and is often undetected or inadequately treated. The ingestion of specific foods, including seafood, tree nuts, and wheat, or a nonspecific meal consisting of multiple food components shortly before or after physical exertion, is sometimes, but not always, the principal precipitant of EIA. This article briefly explores the current hypotheses on the role of immunoglobulin E, response mediators, and physiologic changes that bring on EIA, and discusses the current recommendations for diagnosis, including allergen challenge and laboratory testing, emergency care, and long-term prevention and patient follow-up. Accurate diagnosis of EIA is critical to providing lifesaving therapy and care plans to patients at risk. With respect to the medical management of EIA, mainstay therapy with epinephrine is described. For those with a known history of EIA, a comprehensive anaphylaxis action plan is central to successful patient management. Furthermore, patient education is necessary to heighten awareness of the signs and symptoms of EIA and appropriate strategies for allergen avoidance and self-management of anaphylactic episodes with self-injectable epinephrine.